Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.
暂无分享,去创建一个
T. Ruhstaller | M. Borner | A. Kappeler | D. Helbling | A. Roth | D. Dietrich | P. Saletti | D. Koeberle | B. Pestalozzi | W. Mingrone | C. Caspar | A. Trojan | V. Hess | R. Moos | D. Lanz | R. von Moos | Markus Borner | D. Rauch | Arnaud Roth | Andreas Trojan | Daniel Helbling | Doris Lanz
[1] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] E. Van Cutsem,et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Sargent,et al. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? , 2007, The Lancet.
[4] W. Scheithauer,et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer , 2007 .
[5] W. Scheithauer,et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC) , 2007 .
[6] T. Conroy,et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC) , 2007 .
[7] C. Bokemeyer,et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study , 2007 .
[8] John Mendelsohn,et al. Epidermal growth factor receptor targeting in cancer. , 2006, Seminars in oncology.
[9] S. Barni,et al. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Mineur,et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Hilde Tobi,et al. Small proportions: what to report for confidence intervals? , 2005, Pharmacoepidemiology and drug safety.
[12] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[14] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[15] T. Conroy,et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Kerr,et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial , 2003, The Lancet.
[18] R. Stupp,et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Peters,et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. , 2002, European journal of cancer.
[20] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[21] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[22] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[23] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.